Cold Atmospheric Plasma Device for Pediatric Molluscum and Verruca
Status:
Not yet recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study is going to test a cold atmospheric plasma device (CAP), in particular a floating
electrode-dielectric barrier device (FE-DBD), to treat warts and molluscum. The treatment
device in this study generates cold atmospheric plasma (gaseous ionized molecules) to rid the
virus from the body. Based on the successes of previous dermatologic studies, FE-DBD is being
tested for this study to treat warts and molluscum. Patients will be enrolled to test the
efficacy and safety of this device. The duration of the study is 4-12 weeks depending on
treatment clearance. The number of lesions will be chosen by the dermatologist. Patients will
receive standard of care therapy and/or NTAP depending on the number of lesions.